Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

5 Things You Need to Know If You Buy Viking Therapeutics Stock Today: https://g.foolcdn.com/editorial/images/770619/cheering-person-with-laptop.jpg
5 Things You Need to Know If You Buy Viking Therapeutics Stock Today

What's the hottest biotech stock on the market right now? If we limit the list only to those with market caps of at least $500 million, it's Viking Therapeutics (NASDAQ: VKTX). So far in 2024

EQS-News: STRATEC REPORTS RESULTS FOR 2023 FINANCIAL YEAR: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
EQS-News: STRATEC REPORTS RESULTS FOR 2023 FINANCIAL YEAR
EQS-News: STRATEC REPORTS RESULTS FOR 2023 FINANCIAL YEAR
Why Medical Properties Trust Stock Popped Today: https://g.foolcdn.com/editorial/images/770930/rent-blocks-real-estate-rental.jpg
Why Medical Properties Trust Stock Popped Today

Shares of Medical Properties Trust (NYSE: MPW) soared 18.6% on Wednesday after the largest tenant of the healthcare facilities-focused real estate investment trust (REIT) announced a deal to sell

Why Medical Properties Trust Stock Popped Today: https://g.foolcdn.com/editorial/images/770930/rent-blocks-real-estate-rental.jpg
Why Medical Properties Trust Stock Popped Today

Shares of Medical Properties Trust (NYSE: MPW) soared 18.6% on Wednesday after the largest tenant of the healthcare facilities-focused real estate investment trust (REIT) announced a deal to sell

Tufts Medicine and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve the Greater Boston Area: https://mms.businesswire.com/media/20240327491580/en/2082072/5/ACHCTuftsphoto.jpg
Tufts Medicine and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve the Greater Boston Area


Tufts Medicine, a leading Massachusetts integrated, academic health system, and Acadia Healthcare Company, the largest standalone provider of behavioral health services in the U.S., today held a

Why Viking Therapeutics Stock Is Skyrocketing Today: https://g.foolcdn.com/editorial/images/770697/scientists-smiling-and-shaking-hands.jpg
Why Viking Therapeutics Stock Is Skyrocketing Today

Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an

Viking Therapeutics: Buy, Sell, or Hold?: https://g.foolcdn.com/editorial/images/767479/doctor-talks-to-patient-while-holding-pill-bottle.jpg
Viking Therapeutics: Buy, Sell, or Hold?

When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?: https://g.foolcdn.com/editorial/images/770468/ozempic.jpg
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those

2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever: https://g.foolcdn.com/editorial/images/770308/individual-investors-at-home-getty.jpg
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever

Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't

2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever: https://g.foolcdn.com/editorial/images/770308/individual-investors-at-home-getty.jpg
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever

Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't

Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?: https://g.foolcdn.com/editorial/images/770269/sell-stock.jpg
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?

Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in

Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?: https://g.foolcdn.com/editorial/images/770269/sell-stock.jpg
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?

Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in

Is Viking Therapeutics Stock a Millionaire Maker?: https://g.foolcdn.com/editorial/images/769788/doctor-discussing-a-report-with-people.jpg
Is Viking Therapeutics Stock a Millionaire Maker?

There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move: https://g.foolcdn.com/editorial/images/770146/stock-chart-on-tablet-young-woman.jpg
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks.

Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics

Where Will Viking Therapeutics Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/769981/scientist-looking-through-microscope.jpg
Where Will Viking Therapeutics Stock Be in 10 Years?

Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight

A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now: https://g.foolcdn.com/editorial/images/769710/dog-with-owners-looking-at-laptop.jpg
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now

Does a rising tide really lift all boats? We could soon find out if the adage applies to the stock market.

A bull market is now well underway. The S&P 500 has soared more than 30% over the last 12

A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now: https://g.foolcdn.com/editorial/images/769710/dog-with-owners-looking-at-laptop.jpg
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now

Does a rising tide really lift all boats? We could soon find out if the adage applies to the stock market.

A bull market is now well underway. The S&P 500 has soared more than 30% over the last 12

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?: https://g.foolcdn.com/editorial/images/769667/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?: https://g.foolcdn.com/editorial/images/769667/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

Will Pfizer Be a Trillion-Dollar Stock by 2035?: https://g.foolcdn.com/editorial/images/769917/scientists-in-a-lab-monitor-microscope.jpg
Will Pfizer Be a Trillion-Dollar Stock by 2035?

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue

Will Pfizer Be a Trillion-Dollar Stock by 2035?: https://g.foolcdn.com/editorial/images/769917/scientists-in-a-lab-monitor-microscope.jpg
Will Pfizer Be a Trillion-Dollar Stock by 2035?

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue

Could Viking Therapeutics Become the Next Eli Lilly?: https://g.foolcdn.com/editorial/images/770100/gettyimages-1220595235.jpg
Could Viking Therapeutics Become the Next Eli Lilly?

Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.

Doctors have been prescribing Mounjaro and the

Want Decades of Passive Income? 2 Stocks to Buy Now.: https://g.foolcdn.com/editorial/images/769462/physician-shaking-patients-hand.jpg
Want Decades of Passive Income? 2 Stocks to Buy Now.

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And

EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act